In the European Union<unk>  is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control: * in adults inadequately controlled on their maximally tolerated dose of metformin alone; * in adults inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin; * in adults already being treated with the combination of<unk>  and metformin as separate tablets. In the United States it is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.
Empagliflozin/metformin
Canagliflozin/metformin
Dapagliflozin/metformin
Pioglitazone/metformin
Glibenclamide/metformin
Insulin degludec/liraglutide
Dapagliflozin/saxagliptin/metformin
Dapagliflozin/saxagliptin